08:06 EDT Scholar Rock (SRRK) up 14% at $35.41 after disclosing results from EMBRAZE trial
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock Announces Positive Phase 2 Trial Results
- Scholar Rock announces results from EMBRAZE trial
- Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
- Positive Outlook on Scholar Rock’s Apitegromab Driven by Promising Trial Results and Potential in Obesity and SMA Treatment
- Promising Potential in Scholar Rock’s Obesity and SMA Programs Drives Buy Rating